18F-DCFPyL PET/CT在前列腺癌生化失败患者中检出嗜酸细胞瘤
一例76岁前列腺癌放疗后生化失败患者,Tc-MDP骨扫描和诊断CT未检出恶性病变,PSMA靶向18F-DCFPyL PET/CT显示淋巴结病变及左肾与囊肿和活检证实的嗜酸细胞瘤相关的放射性缺损区。PSMA在多种实体瘤新生血管中表达,文献报道约50%嗜酸细胞瘤与76%透明细胞肾癌可见PSMA表达,无论18F-DCFPyL摄取如何均需活检确认。
要点
- 前列腺癌生化失败患者18F-DCFPyL PET/CT可显示淋巴结病变及左肾嗜酸细胞瘤相关放射性缺损。
- 文献报道约50%嗜酸细胞瘤与76%透明细胞肾癌可见PSMA表达。
- 无论18F-DCFPyL摄取如何,嗜酸细胞瘤均需活检确认。
核心结论
- 18F-DCFPyL PET/CT在前列腺癌生化失败患者中检出淋巴结病变及左肾与囊肿和活检证实的嗜酸细胞瘤相关的放射性缺损区。
研究设计与样本
- 单例76岁男性前列腺癌放疗后生化失败病例报告,行Tc-MDP骨扫描、诊断CT及18F-DCFPyL PET/CT检查。
主要发现
- Tc-MDP骨扫描和诊断CT未检出恶性病变。
- 18F-DCFPyL PET/CT显示淋巴结病变及左肾与囊肿和活检证实的嗜酸细胞瘤相关的放射性缺损区。
- 文献报道PSMA表达见于约50%的嗜酸细胞瘤与76%的透明细胞肾癌。
关键数值与推荐
- PSMA在多种实体瘤新生血管中表达,文献报道约50%嗜酸细胞瘤与76%透明细胞肾癌可见PSMA表达。
临床怎么用
- 无论18F-DCFPyL摄取如何,嗜酸细胞瘤均需活检确认。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 76-year-old man with biochemical failure after primary radiotherapy for prostate cancer had no malignant disease detected on Tc-MDP bone scan and diagnostic CT. Prostate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein, is overexpressed in prostate cancer cells. The PSMA-targeted F-DCFPyL PET/CT demonstrated lymph node disease and photopenic defects in the left kidney associated with a cyst and biopsy-proven oncocytoma. Prostate-specific membrane antigen is expressed in the neovasculature of several solid tumors. It has been reported that PSMA expression is seen in approximately 50% of oncocytoma versus 76% of clear cell renal carcinomas. Biopsy confirmation is needed regardless of F-DCFPyL avidity.
引用
- Li J, Xu R, Kim CK, et al. 18F-DCFPyL PET/CT in Oncocytoma. Clin Nucl Med. 2018. PMID: 30300203. doi:10.1097/RLU.0000000000002301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。